Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy

Archives of Dermatology

Volumn 141, Issue 1, 2005, Pages 60-67

  Oseroff, Allan R ^a,b   Shieh, Sherry ^a,b   Frawley, Noreen P ^a,b   Cheney, Richard ^a   Blumenson, Leslie E ^c   Pivnick, Eniko K ^d   Bellnier, David A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c BioStats   (Israel)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID;

ADOLESCENT; ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BODY SURFACE; CASE REPORT; CHILD; DYE LASER; FEMALE; HAMARTOMA; HUMAN; MALE; MORBIDITY; OUTCOMES RESEARCH; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL;

ADOLESCENT; AMINOLEVULINIC ACID; BASAL CELL NEVUS SYNDROME; CHILD; FEMALE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 12444330347     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.1.60     Document Type: Article

References (49)

1. RJ Gorlin, RW Goltz. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med. 1960;262:908-912.
2. RJ Gorlin. Mevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 1987;66:98-113.
3. Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001;10:757-762.
4. Epstein E Jr. Genetic determinants of basal cell carcinoma risk. Med Pediatr Dncol. 2001:36:555-558.
5. Grachtchouk M, Yu Z, Sasaki H, et al. Basal cell carcinomas in mice overexpressing GN2 in skin. Nat Genet. 2000;24:216-217.
6. Evans FB. The incidence of Gorlin syndrome in 173 consecutive cases of meduloblastoma. Br J Cancer. 1957;64:959-961.
7. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997;276:817-821.
8. Grachtchouk V, Grachtchouk M, Lowe J, et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J. 2003;22:2741-2751.
9. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299-308.
10. Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet. 1994;50:282-290.
11. Walter AW, Pivnick EK, Bale AE, Kun LE. Complications of the nevoid basal cell carcinoma syndrome: a case report. J Pediatr Hematol Oncol. 1997;19:258-262.
12. Kennedy JC, Pettier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6:143-148.
13. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146:552-567.
14. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144:832-840.
15. Varma S, Wilson H, Kurwa HA, et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol. 2001;144:567-574.
16. Rittenhouse-Diakun K, Leengoed H, Morgan J, et al. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem Photobiol. 1995;61:523-528.
17. Chiritescu E, Matoney ME. Acrochordons as a presenting sign of nevoid basal cell carcinoma syndrome. J Am Acad Dermatol. 2001;44:789-794.
18. Wheeler CE Jr, Carroll MA, Groben PA, Briggaman RA, Prose NS, Davis DA. Autosomal dominantly inherited generalized basaloid follicular hamartoma syndrome: report of a new disease in a North Carolina family. J Am Acad Dermatol. 2000;43:189-206.
19. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6:429-453.
20. Bellnier DA, Dougherty TJ. A preliminary pharmacokinetic study of intravenous Photofrin in patients. J Clin Laser Med Surg. 1996;14:311-314.
21. Gartmann H, Groth W, Quinkler C. Multiple basaloid follicular hamartomas in 2 members of a family with Gorlin-Goltz syndrome [in German]. Z Hautkr. 1989;64:915-918.
22. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer. 1998;77:1386-1394.
23. Henderson B, Vaughan F, Babich S, Zollo D, Cooper B, Greco O. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res. 2000;60:525-529.
24. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992;14:275-292.
25. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical delta-amino levulinic acid sensttization and laser irradiation. Br J Dermatol. 1994;130:743-751.
26. Cairnduff F, Stringer MR, Hudson EJ, Ash OV, Brown SB. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer. 1994;69:605-608.
27. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol. 1995;133:282-288.
28. Caizavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B. 1995;29:53-57.
29. Lui H, Saiasche S, Koilias N, et al. Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. Arch Dermatol. 1995;131:737-738.
30. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer. 1997;79:2282-2308.
31. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol. 1998;134:248-249.
32. Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol. 1998;134:821-826.
33. Soler AM, Warloe T, Tausjo J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol. 1999;79:204-206.
34. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol. 2001;137:319-324.
35. Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed. 2003;19:134-141.
36. Sitnik TM, Henderson BW. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol. 1998;67:462-466.
37. Szeimies RM, Sassy T, Landthaler M. Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol. 1994;59:73-76.
38. Henderson BW, Sitnk-Busch TM, Vaughan LA. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent. Photochem Photobiol. 1999;70:64-71.
39. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers: current review and update. Mol Immunol. 2003;39:1133-1136.
40. Karrer S, Baumler W, Abels C, Hohenleutner U, Landthaler M, Szeimies RM. Long-pulse dye laser for photodynamic therapy: investigations in vitro and in vivo. Lasers Surg Med. 1999;25:51-59.
41. Szeimies RM, Mein R, Baumler W, Heine A, Landthaler M. A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Derm Venereol. 1994;74:117-119.
42. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol. 2004;140:33-40.
43. Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol. 2003;139:1313-1320.
44. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2:629-635.
45. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149:1242-1249.
46. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140:17-23.
47. Slender IM, Bech-Thomsen N, Poulsen T, Wulf HC. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol. 1997;66:493-496.
48. Sharfaei S, Viau G, Lui H, Bouffard D, Bissonnette R. Systemic photodynamic therapy with aminolaevulinic acid delays the appearance of ultraviolet-induced skin tumours in mice. Br J Dermatol. 2001;144:1207-1214.
49. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002;62:1604-1608.